Boey
Boey is the brand name for trenibotulinumtoxinE, a botulinum toxin type E product from AbbVie / Allergan. It is distinct from Botox and Botox Cosmetic: Boey uses a different toxin serotype and has its own product identity, clinical program, potency units, and regional approvals.
In June 2026, Health Canada listed Boey under AbbVie Corporation. In July 2026, the European Commission approved Boey for a specified glabellar-line indication. AbbVie had previously reported a U.S. Complete Response Letter for the product’s Biologics License Application, so Boey should not be treated as FDA approved.
Product Identity
Section titled “Product Identity”| Field | Reference point |
|---|---|
| Brand | Boey |
| Nonproprietary name | TrenibotulinumtoxinE |
| Toxin type | Botulinum toxin type E |
| Developer and commercial company | Allergan Aesthetics, an AbbVie company |
| Canadian authorization holder | AbbVie Corporation (AbbVie Canada product monograph 🔗) |
| EEA marketing authorization holder | AbbVie Ltd (EMA authorization details 🔗) |
| Approved markets documented here | Canada and the European Economic Area |
| Comparison limit | A separate type E product, not a Botox variant or a type A unit comparator |
Approval Context
Section titled “Approval Context”| Region | Current reference point | Interpretation |
|---|---|---|
| Canada | Health Canada’s innovative-drug register lists Boey and trenibotulinumtoxinE under AbbVie Corporation with a June 22, 2026 notice-of-compliance date. | The listing establishes a Canadian regulatory record; local product information controls the authorised use. |
| European Economic Area | The European Commission approved Boey on July 17, 2026 for temporary improvement of moderate-to-severe glabellar lines at maximum frown in adults when the lines have an important psychological impact. | This is a region-specific indication across the EEA, not a global label. |
| United States | AbbVie reported a Complete Response Letter for the BLA on April 23, 2026. | The BLA was not approved in its submitted form; Boey is not documented here as FDA approved. |
Type E And Product-Specific Interpretation
Section titled “Type E And Product-Specific Interpretation”Type E cleaves SNAP-25, as type A does, but at a different site. That shared mechanism does not make Boey comparable or interchangeable with type A products such as Botox, Dysport, Xeomin, Jeuveau, Daxxify, Letybo, or Relfydess.
AbbVie reported that clinical studies of trenibotulinumtoxinE observed onset as early as eight hours and effects lasting approximately two to three weeks in the studied glabellar-line setting. Those results are product- and study-specific. They do not establish a general type E duration rule or a clinical ranking against another product.
Graph Connections
Section titled “Graph Connections”AbbVie / Allergan provides the company and Allergan Aesthetics context, while botulinum toxin type E explains the serotype distinction. Botox is the closest corporate-franchise comparison anchor, but Boey is not part of the onabotulinumtoxinA product family.
Darin J. Messina, Ph.D. connects the product to AbbVie’s aesthetics R&D organization and was named in AbbVie’s July 2026 EU-approval announcement.